Advanced Enzyme Technologies Limited has increased its stake in its wholly owned subsidiary, Advanced Nutrazyme Private Limited (ANPL), through an additional investment of ₹2.5 million. The company completed this transaction by subscribing to a rights issue of 2,50,000 equity shares with a face value of ₹10 each. This move strengthens the parent company's financial commitment to its subsidiary.

With this infusion, the total investment in ANPL has risen to ₹3 million. This capital is divided into 3,00,000 equity shares of ₹10 each, consolidating Advanced Enzyme Technologies' ownership position. The rights issue serves as a mechanism for the subsidiary to raise capital directly from its existing shareholder.

Investment Details

The transaction details regarding the additional investment are outlined below:

The disclosure was filed with the stock exchanges on June 06, 2026. The intimation references a prior letter dated August 02, 2025, regarding the proposed investment. The filing was signed by Sanjay Basantani, Company Secretary and Head – Legal.

Advanced Enzyme Technologies Limited has filed the transcript of its earnings conference call held on May 12, 2026, with the stock exchanges. The call discussed the audited financial results for the quarter and year ended March 31, 2026. The audio recording is available on the company's website.

Consolidated Financial Performance

The company reported its highest-ever quarterly and annual revenue for the fiscal year ended March 2026. Revenue from operations for Q4 FY26 stood at ₹2,034 million, a growth of 22% year-on-year and 18% sequentially. For the full year FY26, revenue increased by 17% to ₹7,458 million.

Profitability metrics showed significant improvement. Profit after tax (PAT) for Q4 FY26 surged 69% year-on-year to ₹453 million, compared to ₹260 million in the corresponding quarter of the previous year. For the full year, PAT grew by 30% to ₹1,736 million. EBITDA for the quarter stood at ₹632 million, up 39% year-on-year, with margins remaining strong at 31%.

Segmental and Geographical Highlights

All four business segments delivered year-on-year growth. The Human Healthcare segment remained the largest contributor, accounting for 63% of total revenue with a 24% increase to ₹1,281 million. Animal Healthcare revenue grew 19% to ₹250 million, while Bio-Processing increased by 17% to ₹324 million. The Specialized Manufacturing segment grew 17% to ₹180 million.

Domestic sales accounted for 52% of total revenue in Q4 FY26, rising 51% year-on-year to ₹1,061 million. International sales stood at ₹973 million, with Asia (ex-India) recording 38% growth and the rest of the world reporting 44% growth.

Operational Updates

The company filed two food enzyme dossiers with the European Food Safety Authority (EFSA) and three with the US FDA during the year. Management anticipates approval for anti-inflammatory products filed in the European region during the current fiscal year. The new R&D center in Nashik is expected to become fully operational in the latter half of FY27.